Fernstrom M H, Fernstrom J D
Weight Management Center, UPMC Health System, Pittsburgh, Pennsylvania 15213-2593, USA.
Int J Clin Pract. 2002 Nov;56(9):683-6.
Obesity is associated with an increased risk for a wide variety of chronic health conditions. Despite this fact, less than half of obese patients are advised by healthcare professionals to lose weight. Creating a viable plan for losing weight and maintaining weight loss is difficult. Lifestyle change is always the cornerstone of treatment, but two new therapeutic agents approved for long-term use, sibutramine and orlistat, can help maximise success. Increased weight loss can lead to reductions in the risk of obesity-related co-morbidities. Sibutramine and orlistat offer new weight reduction opportunities for obese patients.
肥胖与多种慢性健康状况风险增加相关。尽管如此，医疗保健专业人员建议减肥的肥胖患者不到半数。制定一个可行的减肥及维持体重减轻的计划很困难。生活方式改变始终是治疗的基石，但两种新批准可长期使用的治疗药物西布曲明和奥利司他，有助于使减肥成效最大化。体重减轻增加可降低肥胖相关合并症的风险。西布曲明和奥利司他为肥胖患者提供了新的减肥机会。
